|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.9339 - 0.9339|
|52-week range||0.9339 - 0.9339|
|Beta (5Y monthly)||1.66|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., August 09, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.
CAMBRIDGE, Mass., August 04, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).